Board of Directors

The composition of Novozymes' Board of Directors following the Annual Shareholders' Meeting on February 22, 2017.

  • joergen
    Jørgen Buhl RasmussenBorn 1955.

    Chairman of the Board since 2017. Adjunct Professor at Copenhagen Business School. Member of the Board since 2011. Member of the Audit Committee. Elected for one year at a time.

    Board positions
    Member: IFC Europe A/S, Axcel Advisory Board, DI's Permanent Committee on Business Policies

    Chairman of Nomination and Remuneration Committee

    Chairman: F. Uhrenholt A/S

    Special competencies
    International business and management experience, specifically within sales, marketing, branding and acquisitions Experience in finance and accounting matters.

  • agnete
    Agnete Raaschou-NielsenBorn 1957.

    Vice Chairman of the Board since 2017. Member of the Board since 2011. Elected for one year at a time

    Board positions
    Chairman: Arkil Holding A/S, Brdr. Hartmann A/S
    Vice Chairman: Dalhoff Larsen & Horneman A/S, Danske Invest, Solar A/S
    Member: Aktieselskabet Schouw & Co., Danske Invest Management A/S, Icopal Holding A/S

    Member of Audit Committees:
    Aktieselskabet Schouw & Co., Solar A/S

    Special competencies
    Expertise in business development and acquisitions, macroeconomics and intellectual property rights. Experience in finance and accounting matters.

  • heinz
    Heinz-Jürgen BertramBorn 1958.

    President & CEO, Symrise AG, Germany. Doctoral degree, PhD (Chemistry). Member of the Board since 2015. Elected for one year at a time.

    Board positions
    Member: Rockwool International A/S
     
    Special competencies
    International business and management experience, specifically in converting biotechnology research into commercial products and solutions.

  • lars
    Lars GreenBorn 1967.

    Senior Vice President, Finance & Operations, Novo Nordisk Inc. (USA), MSc (Business Administration). Member of the Board since 2014. Chairman of the Audit Committee. Elected for one year at a time.

    Special competencies
    In-depth knowledge of the Novo Group's business, international experience from managing global biotech and biopharma companies, and financial and accounting expertise.
  • mathias
    Mathias UhlénBorn 1954.

    Professor, the Royal Institute of Technology (Kungliga Tekniska Högskolan), Sweden, and the Technical University of Denmark (DTU). Member of the Board since 2007. Elected for one year at a time.

    Board positions
    Chairman: Atlas Antibodies AB, Antibodypedia AB
    Vice Chairman: Affibody AB
    Member: Alligator AB, Bure Equity AB, SweTree Technologies AB
     
    Special competencies
    Broad experience in research and biotechnology.
  • kim
    Kim StrattonBorn 1962.

    Head of International Commercial, Shire International GmbH (Switzerland). Member of the Nomination and Remuneration Committee

    Special competencies
    Broad international commercial experience, including in sales and marketing, emerging markets, innovation pipeline management and sustainability.

  • kasim
    Kasim KutayBorn 1965.

    CEO, Novo A/S

    Special competencies
    Broad experience within biotechnology, and in mergers and acquisitions, as well as financial and accounting expertise.

  • lena_bech
    Lena Bech HolskovBorn 1967.

    Safety Adviser. Employee representative. Member of the Board since 2013. Elected for four years at a time.

  • anders_hentze
    Anders Hentze KnudsenBorn 1959.

    Senior Operator. Employee representative. Member of the Board since 2013. Elected for four years at a time.

  • lars_bo_koppler
    Lars Bo KøpplerBorn 1962.

    Technician. Employee representative. Member of the Board since 2010. Elected for four years at a time.
     
    Employee elected member of the board of Novo Nordisk Foundation since 2014. Elected for a four year period.